Economist: Pharmas Are Protected 'Fragile Little Birds'
This article was originally published in Scrip
Executive Summary
While makers of high-priced specialty drugs in the US like to think they are free-enterprisers operating in the competitive markets, what those firms really are, argued Princeton economics professor Uwe Reinhardt, are "fragile little birds" protected by the government, which he said "carefully shields" the companies from the "harsh vagaries of truly free, competitive markets."